List of Excipients in Branded Drug FLYRCADO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GE Healthcare Inc	FLYRCADO	flurpiridaz f-18	0407-8787	ALCOHOL	2029-09-27
GE Healthcare Inc	FLYRCADO	flurpiridaz f-18	0407-8787	ASCORBIC ACID	2029-09-27
GE Healthcare Inc	FLYRCADO	flurpiridaz f-18	0407-8787	HYDROXYPROPYL BETADEX	2029-09-27
GE Healthcare Inc	FLYRCADO	flurpiridaz f-18	0407-8787	SODIUM HYDROXIDE	2029-09-27
GE Healthcare Inc	FLYRCADO	flurpiridaz f-18	0407-8787	WATER	2029-09-27

FLYRCADO Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

FLYRCADO (flurpiridaz F 18 injection) is a sterile, single-use positron emission tomography (PET) radiopharmaceutical for myocardial perfusion imaging. Its excipient opportunity is narrow but commercially relevant: the product requires high-purity injectable materials, low-metal manufacturing controls, validated sterile processing, and reliable supply near radiopharmacy sites. The largest opportunities are in qualified excipient supply, radiopharmaceutical contract manufacturing, automated dispensing, distribution infrastructure, and PET-center adoption rather than in high-volume excipient sales.

What is FLYRCADO and how is it regulated?

FLYRCADO contains flurpiridaz labeled with fluorine-18. The FDA approved it on September 27, 2024, for PET myocardial perfusion imaging in adults with known or suspected coronary artery disease.[1,2]

Attribute	FLYRCADO profile
Brand	FLYRCADO
Active ingredient	Flurpiridaz F 18
Dosage form	Sterile injectable solution
Route	Intravenous
Therapeutic category	Diagnostic radiopharmaceutical
Imaging modality	PET myocardial perfusion imaging
FDA pathway	New drug application
FDA approval	September 27, 2024
Sponsor	Lantheus Medical Imaging, Inc.
Radioisotope	Fluorine-18
Physical half-life	Approximately 109.8 minutes
Primary commercial customers	Nuclear pharmacies, PET centers, hospitals and imaging networks

The short half-life materially changes the excipient strategy. FLYRCADO must be manufactured, released, shipped and administered within a tightly controlled time window. The product cannot use a conventional national distribution model in which finished doses remain in inventory for days or weeks.

What excipients are used in FLYRCADO?

The U.S. prescribing information identifies sodium chloride and ethanol among the inactive ingredients and describes the product as a sterile injectable preparation.[1]

Excipient profile

Excipient or material	Likely functional role	Commercial significance
Sodium chloride	Isotonicity adjustment and injectable vehicle	Requires parenteral grade, tight elemental impurity control and dependable supply
Ethanol	Solubilization and formulation support	Requires controlled residual level, validated compatibility and low extractables risk
Water for injection	Aqueous vehicle	Must meet compendial and sterile manufacturing requirements
Container-closure components	Dose containment and transport	Must limit adsorption, leakage, extractables and radiation-related degradation
Sterile filters and single-use assemblies	Aseptic processing	Require radiopharmaceutical-compatible validation and short processing cycles

The formulation is comparatively simple. That limits the opportunity for proprietary excipient innovation but increases the value of manufacturing execution. In a short-lived radiopharmaceutical, a theoretically superior excipient has little commercial value if it complicates synthesis, delays release testing, reduces radiochemical yield or introduces a new quality-control failure mode.

How should the FLYRCADO excipient strategy be designed?

The optimal strategy is a low-complexity formulation with a narrow supplier base for critical materials and a qualified backup source for each high-risk component.

1. Prioritize radiochemical stability

Fluorine-18 products can be exposed to radiolysis, particularly at higher activity concentrations. Ethanol can help control solubility and may reduce some radiolytic effects, but its concentration must remain within the validated formulation range. Reformulation would require assessment of:

• Radiochemical purity over the labeled shelf life
• Chemical purity and degradation products
• pH and osmolality
• Residual solvent levels
• Injectability and syringeability
• Compatibility with automated dose dispensers
• Container-closure integrity after irradiation and transport

A change from ethanol to another co-solvent would have a high regulatory burden because it could affect radiochemical yield, impurity formation, toxicological exposure and process reproducibility.

2. Use compendial, low-variability materials

Sodium chloride and water for injection are standard materials, but radiopharmaceutical production imposes additional requirements. Suppliers should be assessed for:

• Lot-to-lot elemental impurity control
• Low peroxide and oxidant content
• Low particulate burden
• Consistent pH and conductivity
• Sterility and endotoxin performance
• Supply continuity near manufacturing sites
• Documentation suitable for an NDA change-control system

Elemental impurities can affect radiolabeling chemistry and radiochemical purity even when the excipient meets a general injectable specification. A supplier with a strong conventional injectable profile may still require additional qualification for radiopharmaceutical use.

3. Control metals and reactive impurities

The flurpiridaz labeling process depends on fluorine-18 chemistry and precursor handling. Trace metals, oxidants, residual cleaning agents and reactive leachables can reduce yield or increase unlabeled impurities. FLYRCADO manufacturers should establish a critical-material program covering:

• Sodium chloride
• Ethanol
• Water systems
• Vials and closures
• Tubing and sterile filters
• Single-use bags
• Transfer lines
• Cleaning agents
• Precursor and isotope-contact materials

This creates an opportunity for suppliers able to provide enhanced certificates of analysis, elemental impurity data and rapid lot-release documentation.

4. Design for distributed production

Because fluorine-18 decays rapidly, a national finished-product inventory is not practical. The more likely model is regional or hub-and-spoke production using cyclotron capacity, radiopharmacy networks and scheduled PET procedures.

Excipients should therefore be packaged in formats that support:

• Frequent small-batch production
• Short manufacturing campaigns
• Low-volume sterile compounding
• Automated dispensing
• Minimal operator intervention
• Standardized documentation across multiple sites

Small-volume, ready-to-use excipient presentations may have more commercial value than bulk containers, particularly for hospital-based radiopharmacies.

What commercial opportunities exist for excipient suppliers?

The direct excipient market is modest because each administered dose contains a small volume of formulation. The higher-value opportunities sit around qualification, manufacturing support and workflow integration.

Qualified injectable excipients

Suppliers can compete for sodium chloride, ethanol and water-for-injection supply by offering:

• Radiopharmaceutical-specific quality packages
• Low-metal and low-peroxide specifications
• Rapid release certificates
• Dual-site manufacturing
• Smaller sterile presentations
• Change-notification controls
• Regional warehousing

A supplier that provides only commodity pricing will have limited differentiation. A supplier that reduces batch-release risk and supports regulatory filings can command stronger commercial terms.

Radiopharmaceutical CDMO services

A CDMO can offer value by combining:

• Cyclotron access
• Fluorine-18 production
• Radiolabeling
• Sterile filtration
• Aseptic filling
• Quality-control testing
• Dose calibration
• Regional delivery

The formulation itself is not difficult to reproduce conceptually. The barriers are validated radiochemistry, site licensing, hot-cell infrastructure, radiation safety, sterility assurance and time-sensitive logistics.

Container-closure and delivery systems

Commercial opportunities include low-adsorption vials, radiation-compatible closures, calibrated syringes and automated dispensing systems. Product-contact components should be evaluated for:

• Flurpiridaz adsorption
• Ethanol compatibility
• Extractables and leachables
• Radiation exposure
• Dose accuracy
• Shielding compatibility
• Container-closure integrity

Automated dispensing systems can reduce personnel exposure and improve dose consistency. Suppliers with validated interfaces for nuclear pharmacy operations may capture more value than suppliers selling standard vials alone.

PET-center infrastructure

FLYRCADO adoption depends on access to PET scanners, radiopharmacy scheduling and reimbursement. Commercial opportunities include:

• PET myocardial perfusion imaging expansion
• Cyclotron and radiopharmacy partnerships
• Mobile PET services
• Hospital imaging-network contracts
• Dose-management software
• Scheduling systems that coordinate production with patient appointments

The product may expand PET myocardial perfusion use in sites that currently rely on SPECT, subject to local equipment, staffing and reimbursement economics.

What formulation patents protect FLYRCADO?

The key intellectual-property assets are likely to fall into four groups:

1. Flurpiridaz composition-of-matter patents.
2. Radiolabeling and precursor-production patents.
3. Formulation and radiochemical-stability patents.
4. Methods of use for PET myocardial perfusion imaging.

The commercial strength of the estate will depend less on the basic sodium-chloride formulation than on composition-of-matter coverage, precursor claims, radiolabeling processes and method-of-use claims.

Orange Book and patent diligence

FLYRCADO is an FDA-approved drug and its NDA may have associated patent and regulatory-exclusivity information in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[3] A current diligence review should distinguish among:

• Listed patents
• Patent expiration dates
• Pediatric exclusivity
• New chemical entity exclusivity
• Patent-term extension
• Method-of-use claims
• Process patents not listed in the Orange Book
• Manufacturing know-how that is not publicly disclosed

No accurate business conclusion should rely on the formulation alone. A simple sterile saline-and-ethanol formulation may be difficult to use as a durable blocking patent unless supported by specific concentration, stability, radiochemical purity or manufacturing claims.

When does FLYRCADO lose exclusivity?

The FDA approval establishes regulatory exclusivity, but the precise end date depends on the approved exclusivity category and any applicable patent-term adjustment or extension. FLYRCADO’s commercial protection should be modeled in separate layers:

Protection layer	Business impact
Composition-of-matter patents	Potentially strongest barrier to a competing flurpiridaz product
Formulation patents	May limit substantially similar injectable formulations
Process patents	Can raise manufacturing costs but may be avoidable through design-around
Method-of-use patents	May protect specified imaging uses after composition claims expire
New chemical entity exclusivity	Can restrict certain abbreviated applications during the statutory period
Orphan or pediatric exclusivity	Applies only if the FDA grants the relevant designation
Trade secrets	May protect precursor synthesis, radiolabeling and release procedures

A conventional small-molecule generic pathway may not be the only competitive threat. A competing PET radiopharmaceutical with a different active agent could enter without copying FLYRCADO’s formulation or molecule.

What generic entry risks exist for FLYRCADO?

Direct generic risk is likely to be lower than competitive diagnostic-agent risk during the early commercial period because radiopharmaceutical entry requires specialized infrastructure.

Direct flurpiridaz competition

A direct competitor would need to establish:

• Access to fluorine-18 production
• A validated precursor supply
• Reproducible radiolabeling
• Sterile manufacturing
• Comparable imaging performance
• FDA approval
• Regional distribution capacity

The product’s short half-life makes manufacturing scale difficult. A competitor would need geographically distributed production or a dense delivery network.

Alternative PET and SPECT agents

The more immediate commercial threat may come from other myocardial perfusion agents and existing SPECT products. Competitive factors include:

• PET scanner availability
• Image quality
• Stress-testing workflow
• Patient throughput
• Radiation dose
• Reimbursement
• Product availability
• Physician familiarity

FLYRCADO’s commercial adoption will depend on whether improved diagnostic performance and workflow justify PET infrastructure and radiopharmacy costs.

Which companies are likely to participate in the FLYRCADO market?

Lantheus is the primary commercial entity associated with FLYRCADO. The broader market includes:

• Radiopharmaceutical manufacturers
• Hospital nuclear pharmacies
• Independent radiopharmacies
• Cyclotron operators
• PET imaging networks
• Contract development and manufacturing organizations
• Automated dose-dispensing companies
• Injectable excipient suppliers
• Container-closure manufacturers
• Competing PET and SPECT agent developers

The most defensible supplier positions will be regional. A company that controls production capacity, delivery routes and PET-center relationships may have more leverage than a national commodity excipient supplier.

What is the revenue exposure and market opportunity?

Publicly reported FLYRCADO revenue was not established in the FDA approval materials. Revenue forecasting should therefore use operating assumptions rather than reported sales.

A basic commercial model is:

Revenue = administered doses × net price per dose

Key variables include:

• Number of PET myocardial perfusion studies
• Percentage of studies using FLYRCADO
• Average administered activity
• Regional dose price
• Radiopharmacy delivery radius
• Cyclotron availability
• PET scanner utilization
• Reimbursement and hospital contracting
• Product wastage from canceled procedures

Excipient revenue will represent a small fraction of product revenue. The larger addressable opportunity is the infrastructure required to manufacture and deliver doses reliably. Each additional regional production site can increase service coverage while reducing decay-related waste.

How strong is the FLYRCADO commercial and manufacturing position?

FLYRCADO has a strong operational barrier but a narrower formulation barrier.

Factor	Assessment
Excipient complexity	Low
Sterile manufacturing complexity	High
Radiochemistry complexity	High
Distribution complexity	High
Direct formulation differentiation	Moderate to low
Cyclotron dependence	High
PET adoption dependence	High
Generic substitution risk	Moderate
Alternative-agent risk	Moderate to high
Supplier qualification burden	High

The most important manufacturing protections are likely to arise from process knowledge, validated sites, precursor supply, quality systems and logistics rather than from the excipient composition alone.

Key Takeaways

• FLYRCADO is a fluorine-18 PET myocardial perfusion agent approved by the FDA in September 2024.
• Its formulation uses a limited excipient set centered on sodium chloride, ethanol and water for injection.
• The commercial value of excipient supply comes from qualification, low-impurity performance, regulatory support and continuity of supply.
• Radiochemical stability, sterile filtration, container compatibility and rapid batch release are more important than novel excipient design.
• Regional radiopharmacy and cyclotron networks are central to commercial scale because fluorine-18 has a half-life of approximately 109.8 minutes.
• Direct generic competition may be constrained by radiochemistry and logistics, while alternative PET and SPECT agents remain meaningful competitive risks.
• The strongest intellectual-property protection is likely to come from flurpiridaz composition, precursor, radiolabeling and method-of-use claims rather than standard saline-based formulation claims.
• Excipient suppliers should target validated radiopharmaceutical workflows, not commodity volume alone.

FAQs

Can FLYRCADO be reformulated with a different alcohol or co-solvent?

A change would require comparability, stability, toxicology, radiochemical-purity and manufacturing validation. Ethanol substitution should be treated as a high-impact formulation change.

Does FLYRCADO require cold-chain distribution?

The primary constraint is radioactive decay and controlled radiopharmaceutical transport. Storage and shipment conditions must follow the approved labeling and applicable transportation requirements, but rapid delivery is more important than conventional long-duration inventory management.

Are sodium chloride and ethanol the main patent opportunity?

Usually not. Standard excipients are more likely to support manufacturing than to provide broad standalone exclusivity. Commercial protection is more likely to come from the active ingredient, precursor, radiolabeling method or specific stability claims.

Can hospital pharmacies compound FLYRCADO themselves?

Preparation of an FDA-approved radiopharmaceutical requires compliance with applicable FDA, state and Nuclear Regulatory Commission requirements. Hospital production would also require validated radiochemistry, sterile processing and quality-control capabilities.

What is the best supplier entry point for FLYRCADO?

The strongest entry points are qualified injectable materials, radiopharmaceutical CDMO services, validated container-closure systems, automated dose dispensing and regional distribution support.

References

1. U.S. Food and Drug Administration. (2024). FLYRCADO (flurpiridaz F 18 injection) prescribing information. Lantheus Medical Imaging, Inc.

2. U.S. Food and Drug Administration. (2024, September 27). FDA approves first fluorine-18 labeled PET myocardial perfusion imaging agent. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.